GSK Reports Positive Results From Phase 3 Trial for Blenrep in Multiple Myeloma Treatment
GlaxoSmithKline (GSK) Gets a Hold From Goldman Sachs
GlaxoSmithKline To Go Ex-Dividend On November 15th, 2024 With 0.38905 USD Dividend Per Share
GSK Highlights Key Data From Hepatology Portfolio at the AASLD's The Liver Meeting 2024, Emphasising Patient Impact in Areas of High Unmet Need
GSK Gets Health Canada Approval for Blood Cancer Treatment Ojjaara
Top Midday Stories: Tyson Foods Reports Q4 EPS, Revenue Beats; DOJ Reportedly Moving to Block UnitedHealth's Amedisys Acquisition
GSK, Drax, Centrica; What Brokers Said Today
Vesalius Announces Multi-Target Strategic Alliance With GSK to Develop Breakthrough Treatments for People Afflicted With Parkinson's Disease
GSK Target Cut to 1,525p From 2,000p by Jefferies
Jefferies Downgrades GlaxoSmithKline(GSK.US) to Hold Rating, Cuts Target Price to $39.5
GlaxoSmithKline (GSK) Was Downgraded to a Hold Rating at Jefferies
New GSK-sponsored Survey Reveals Unique Gaps in Care and Support Facing Patients With Gynaecologic Cancers
Express News | ViiV Healthcare's DOLCE Study Shows 2-Drug Regimen Dovato Is Highly Effective In Treatment-Naïve People With Advanced HIV, Matching 3-Drug Therapy Efficacy At 48 Weeks
FDA recommends stopping the use of common decongestants in cold medicines, companies like glaxosmithkline (GSK.US) may be affected.
The U.S. Food and Drug Administration (FDA) announced on Thursday that it has proposed to remove oral phenylephrine widely used in cold and cough syrups from the list of active ingredients for over-the-counter medications for nasal congestion, deeming it ineffective.
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction'
Pfizer, GSK, Moderna Struggle in a Shrinking RSV Vaccine Market
GSK, Pfizer And Shionogi's ViiV Healthcare Expands On Real-World Data Supporting Use Of Long-Acting Therapies In Diverse Patient Populations At HIV Glasgow
Moderna Earnings Beat Estimates. But Its Future Still Looks Uncertain. -- Barrons.com
Unusual Options Activity: COIN, MRVL and Others Attract Market Bets, COIN V/OI Ratio Reaches 171.4